Beruflich Dokumente
Kultur Dokumente
706
METHODS
At a workshop held in London in February 2001, a
number of groups presented the data held in their institutions.
Our chosen biosciences partner, Cancer Research and Biostatistics, in discussion with the committee members, subsequently developed the data fields and dictionary. It was
decided that the study period should enlist cases diagnosed
between 1990 and 2000. This interval was chosen as it
represented a relatively short period during which staging
methods had been constant and allowed 5 years of follow-up
before analysis. Cases treated by all modalities of care,
including multimodality treatment, were included. From the
core of contributors who presented at the workshop, data
acquisition was widened to eventually involve 46 sources in
more than 19 countries. These additional sources were identified from the literature by their response to advertisements
in the journals or by contact from individual members of the
committee. A total of 100,869 cases were submitted to the
data center at Cancer Research and Biostatistics. After an
initial sift to exclude cases outside the study period, those for
whom cell type was not known, cases not newly diagnosed at
the point of entry, and those with inadequate information on
stage, treatment, or follow-up, 81,015 cases remained for
analysis. Of these, 67,725 were NSCLC and 13,290 were
small-cell lung cancer (SCLC). Only the NSCLC cases were
included in the analyses of the T, N, and M descriptors and
the subsequent analysis of TNM subsets and stage groupings.
Survival was measured from the date of entry (date of
diagnosis for registries, date of registration for protocols) for
clinically staged data and the date of surgery for pathologically staged data and was calculated by the Kaplan-Meier
method. Prognostic groups were assessed by Cox regression
analysis, using the SAS System for Windows Version 9.0
PHREG procedure.
Where the analyses showed descriptors to have a prognosis that differed from the other descriptors in any T or M
category, two alternative strategies were considered: (1) Retain that descriptor in the existing category, identified by
alphabetical subscripts. For example, additional pulmonary
nodules in the lobe of the primary, considered to be T4 in the
sixth edition,1 would become T4a, whereas additional pulmonary nodules in other ipsilateral lobes, designated as M1 in
the sixth edition,1 would become M1a. (2) Allow descriptors
to move between categories, to a category containing other
descriptors with a similar prognosis, e.g., additional pulmonary nodules in the lobe of the primary would move from T4
to T3, and additional pulmonary nodules in other ipsilateral
lobes would move from M1 to T4. The first strategy had the
advantage of allowing, to a large extent, retrograde compatibility with existing databases. Unfortunately, this generated
a large number of descriptors (approximately 20) and an
N0
N1
N2
N3
Total
419
442
1345
411
2452
144
213
626
6052
12
14
71
33
691
17
41
221
1100
66
78
326
107
2355
134
220
1151
4437
13
5
39
14
616
44
157
790
1678
510
539
1781
565
6114
339
631
2788
13,267
Pathologic Stage
N Stage
Proposed T/M Stage
T1a
T1b
T2a
T2b
T3
T4
M1a
M1b
Total
Copyright 2007 by the International Association for the Study of Lung Cancer
N0
N1
N2
N3
Total
1965
1796
3186
937
2188
224
99
15
10,410
226
343
1123
382
1015
118
42
7
3256
191
327
905
285
1114
217
94
11
3144
4
6
18
4
74
12
4
5
127
2386
2472
5232
1608
4391
571
239
38
16,937
707
Goldstraw et al.
Hazard Ratio
T1a N0
T1b N0
T2a N0
T2b N0
T1abT2ab N1
T3 N0
T12a N2
T3 N1
T4 N01
T2b N2
T3 N2
M1a (N01)
T4 N2
M1a (N2)
T1-M1a N3
M1b (N01)
M1b (N23)
1373
1257
2346
673
1460
2466
1253
1066
354
250
2006
301
239
212
630
553
1287
1.00
1.28
1.80
2.44
2.72
3.67
3.67
4.48
5.47
5.47
6.69
7.39
7.39
9.97
9.97
13.46
16.44
Sample size is the number of cases in the training set classifiable by best stage.
RESULTS
The changes proposed to the current T and M descriptors are highlighted in the full list of descriptors shown in
Table 3. These changes have been reported in detail in this
journal.5,6 The existing N descriptors were validated, and no
changes are proposed.7 The changes proposed suggest that
708
Copyright 2007 by the International Association for the Study of Lung Cancer
T (Primary Tumor)
TX
Sixth Edition
T/M Descriptor
M1b
a
The uncommon superficial spreading tumor of any size with its invasive component limited to the bronchial wall, which may extend proximally to the main bronchus,
is also classified as T1.
b
Most pleural (and pericardial) effusions with lung cancer are due to tumor. In a
few patients, however, multiple cytopathologic examinations of pleural (pericardial)
fluid are negative for tumor, and the fluid is nonbloody and is not an exudate. Where
these elements and clinical judgment dictate that the effusion is not related to the tumor,
the effusion should be excluded as a staging element and the patient should be classified
as T1, T2, T3, or T4.
T1 (2 cm)
T1 (23 cm)
T2 (5 cm)
T2 (57 cm)
T2 (7 cm)
T3 invasion
T4 (same lobe nodules)
T4 (extension)
M1 (ipsilateral lung)
T4 (pleural effusion)
M1 (contralateral lung)
M1 (distant)
Proposed
T/M
T1a
T1b
T2a
T2b
T3
T4
M1a
M1b
N0
N1
N2
N3
IA
IA
IB
IIA
IIB
IIB
IIB
IIIA
IIIA
IV
IV
IV
IIA
IIA
IIA
IIB
IIIA
IIIA
IIIA
IIIA
IIIA
IV
IV
IV
IIIA
IIIA
IIIA
IIIA
IIIA
IIIA
IIIA
IIIB
IIIB
IV
IV
IV
IIIB
IIIB
IIIB
IIIB
IIIB
IIIB
IIIB
IIIB
IIIB
IV
IV
IV
Cells in bold indicate a change from the sixth edition for a particular TNM category.
Copyright 2007 by the International Association for the Study of Lung Cancer
709
Goldstraw et al.
TABLE 5. Sample Sizes for TNM Subsets Providing the Basis for Proposed Changes T1T3 by Best Stage, T4 by Best Stage,
and M1 by Best Stage
T1T3 by Best Stage
Sixth Edition
Descriptor
T1
T1
T2
T2
T2
T3
T4
(2 cm)
(23 cm)
(5 cm)
(57 cm)
(7 cm)
(invasion)
(same lobe nodules)
N0
N1
T4 (extension)
M1 (ipsilateral lung)
Overall
Stage
Sample
Size
Overall
Stage
Sample
Size
Overall
Stage
Sample
Size
Overall
Stage
Sample
Size
T1a
T1b
T2a
T2b
T3
IA
IA
IB
IB>IIA
IB>IIB
IIB
IIIB>IIB
2134
1902
3547
1016
457
3113
174
IIA
IIA
IIB>IIA
IIB
IIB>IIIA
IIIA
IIIB>IIIA
242
360
1184
400
205
1329
70
IIIA
IIIA
IIIA
IIIA
IIIA
IIIA
IIIB>IIIA
257
412
1198
374
211
2735
127
IIIB
IIIB
IIIB
IIIB
IIIB
IIIB
IIIB
19
13
60
20
5
642
5
N0N1
N2N3
Proposed
T/M
Overall
Stage
Sample
Size
Overall
Stage
Sample
Size
T4
IIIB>IIIA
IV>IIIA
432
97
IIIB
IV>IIIB
320
86
M1 by Best Stage
Sixth Edition
Descriptor
T4 (pleural dissemination)
M1 (contralateral lung)
M1 (distant)
N3
Proposed
T/M
T4 by Best Stage
Sixth Edition
Descriptor
N2
Any N
Proposed
T/M
Overall
Stage
Sample
Size
M1a
IIIB>IV
IV
IV
683
230
2800
M1b
Cells in bold indicate a change from the sixth edition for a particular TNM category. Samples sizes for T/M descriptors are summarized across N-stage categories where possible
to highlight the decision points for the proposed stage groupings.
Validation
The proposals derived from the training set of 17,726
cases were internally validated against the validation set of
9133 cases. Details of these analyses are provided in the
companion paper on the validation process and results.10 In
brief, the validation set generated survival curves that were
generally similar to those in the training set and Cox proportional hazards regression analyses that calculated the hazard
ratios between each pair of adjacent stage groups while
710
controlling for cell type, sex, age, and region were all statistically significant using the pathologic staging data. There
were some nonsignificant differences in the early-staged
clinical cases, but this problem was present using both the
proposed system and the existing sixth edition of TNM and
may be the result of an unstable comparison as the validation
set contained only 3863 cases.
External validation was assessed against the Surveillance, Epidemiology, and End Results Program database,
which records best stage and details of this comparison along
with survival curves are provided in our validation paper.10
The Surveillance, Epidemiology, and End Results Program
survival curves using the sixth edition of the TNM Classification of Malignant Tumours and the IASLC proposed system were compared. Generally, both the new system and the
existing performed well, but the separation between the IB
and IIA curves was better in the proposed system, whereas
the new IIA and IIB curves converged at 5 years.
DISCUSSION
Previous revisions to the TNM classification for lung
cancer contained very little internal and no external validation
information. In 1974, the second edition of the TNM Classification of Malignant Tumours 11 incorporated all of the
descriptors suggested by the American Joint Committee on
Cancer Task Force on Lung Cancer.12 Although T, N, and M
Copyright 2007 by the International Association for the Study of Lung Cancer
Copyright 2007 by the International Association for the Study of Lung Cancer
711
Goldstraw et al.
Stage
Stage
Stage
Stage
Hazard Ratio
Comparisons
Sixth Edition
IASLC
Sixth Edition
IASLC
IB vs. IA
IIA vs. IB
IIB vs. IIA
IIIA vs. IIB
IIIB vs. IIIA
IV vs. IIIB
R2
1.31
1.35
1.20
1.30
1.47
1.71
25.86
1.19
1.23
1.46
1.27
1.54
1.64
26.77
0.0001
0.1978
0.4344
0.0001
0.0001
0.0001
0.0035
0.0020
0.0001
0.0001
0.0001
0.0001
Sixth Edition
IASLC
Sixth Edition
IASLC
1.36
1.38
0.0001
0.0001
Adjusted for cell type, sex, age, and region (n 11,536 (8944 events). IASLC,
International Association of the Study of Lung Cancer.
Comparisons
Sixth Edition
IASLC
Sixth Edition
IASLC
IB vs. IA
IIA vs. IB
IIB vs. IIA
IIIA vs. IIB
IIIB vs. IIIA
IV vs. IIIB
R2
1.72
1.28
1.26
1.48
1.27
0.91
29.44
1.55
1.44
1.29
1.47
1.79
0.86
30.40
0.0001
0.0001
0.0002
0.0001
0.0001
0.2921
0.0001
0.0001
0.0001
0.0001
0.0001
0.0974
Sixth Edition
IASLC
Sixth Edition
IASLC
1.35
1.40
0.0001
0.0001
Adjusted for cell type, sex, age, and region (n 15,952 (8988 events). IASLC,
International Association of the Study of Lung Cancer.
712
Occult Carcinoma
0
IA
IB
IIA
Stage IIB
Stage IIIA
Stage IIIB
Stage IV
TX
N0
M0
Tis
T1a, b
T2a
T1a, b
T2a
T2b
T2b
T3
T1, T2
T3
T4
T4
Any T
Any T
N0
N0
N0
N1
N1
N0
N1
N0
N2
N1, N2
N0, N1
N2
N3
Any N
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M1a, b
Copyright 2007 by the International Association for the Study of Lung Cancer
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
ACKNOWLEDGMENTS
Eli Lilly and Company provided funding to support
the work of the International Association for the Study of
Lung Cancer Staging Committee to establish a database
and to suggest revisions to the sixth edition of the TNM
Classification of Malignant Tumours (lung cancer staging)
through a restricted grant. Lilly had no input into the
committees analysis of the data nor suggestions for revisions to the staging system.
REFERENCES
1. Sobin L, Wittekind Ch, eds. TNM Classification of Malignant Tumours,
Sixth Edition. New York: Wiley-Liss, 2002:99103.
2. Mountain CF. Revisions in the international staging system for staging
lung cancer. Chest 1997;111:17101717.
3. Goldstraw P, Crowley JJ. The International Association for the Study of
Lung Cancer International Staging Project on Lung Cancer. J Thorac
Oncol 2006;1:281286.
4. Crowley JJ, LeBlanc M, Jacobson J, et al. Some exploratory tools for
survival analysis. In Lin DY, Fleming TR, eds. Proceedings of the First
Seattle Symposium in Biostatistics: Survival Analysis. New York:
Springer, 1997:199229.
5. Rami-Porta R, Ball D, Crowley JJ, et al. The IASLC Lung Cancer
Staging Project: proposals for revision of the T descriptors in the
forthcoming (seventh) edition of the TNM Classification of Malignant
Tumours. J Thorac Oncol 2007;2:593602.
6. Postmus PE, Brambilla E, Chansky K, et al. The IASLC Lung Cancer
Staging Project: proposals for revision of the M descriptors in the
APPENDIX
IASLC International Staging Committee
P. Goldstraw (Chairperson), Royal Brompton Hospital,
London, UK; H. Asamura, National Cancer Centre Hospital,
Tokyo, Japan; D. Ball, Peter MacCallum Cancer Centre,
Melbourne, Australia; V. Bolejack, Cancer Research and
Biostatistics, Seattle, WA, USA; E. Brambilla, Laboratoire de
Pathologie Cellulaire, Grenoble Cedex, France; P. A. Bunn,
University of Colorado Health Sciences, Denver, CO, USA;
D. Carney, Mater Misericordiae Hospital, Dublin, Ireland; K.
Chansky, Cancer Research and Biostatistics, Seattle, WA,
USA; T. Le Chevalier, Institute Gustave Roussy, Villejuif,
France; J. Crowley, Cancer Research and Biostatistics, Seattle, WA, USA; R. Ginsberg (deceased), Memorial SloanKettering Cancer Center, New York, NY, USA; D. Giroux,
Cancer Research and Biostatistics, Seattle, WA, USA; P.
Groome, Queens Cancer Research Institute, Kingston, Ontario, Canada; H. H. Hansen (retired), National University
Hospital, Copenhagen, Denmark; P. Van Houtte, Institute
Jules Bordet, Bruxelles, Belgium; J.-G. Im, Seoul National
University Hospital, Seoul, South Korea; J. R. Jett, Mayo
Clinic, Rochester, MN, USA; H. Kato (retired), Tokyo Medical University, Tokyo, Japan; C. Kennedy, University of
Copyright 2007 by the International Association for the Study of Lung Cancer
713
Goldstraw et al.
Participating Institutions
O. Visser, Amsterdam Cancer Registry, Amsterdam,
The Netherlands; R. Tsuchiya and T. Naruke (deceased),
Japanese Joint Committee of Lung Cancer Registry, Japan; J.
P Van Meerbeeck, Flemish Lung Cancer Registry-VRGT,
Brussels, Belgium; H. ulzebruck, Thorax-Klinik am Universitatsklinikum, Heidelberg, Germany; R. Allison and L.
Tripcony, Queensland Radium Institute, Herston, Australia;
X. Wang, D. Watson and J. Herndon, Cancer and Leukemia
Group B (CALGB), USA; R. J. Stevens, Medical Research
Council Clinical Trials Unit, London, UK; A. Depierre, E.
Quoix, and Q. Tran, Intergroupe Francophone de Cancerologie Thoracique (IFCT), France; J. R. Jett and S. Mandrekar,
North Central Cancer Treatment Group (NCCTG), USA;
J. H. Schiller and R. J. Gray, Eastern Cooperative Oncology
Group (ECOG), USA; J. L. Duque-Medina and A. LopezEncuentra, Bronchogenic Carcinoma Co-operative Group of
the Spanish Society of Pneumology and Thoracic Surgery
(GCCB-S), Spain; J. J. Crowley, Southwest Oncology Group
(SWOG), USA; J. J. Crowley and K. M. W. Pisters, Bimodality Lung Oncology Team (BLOT), USA; T. E. Strand,
Cancer Registry of Norway; S. Swann and H. Choy, Radia-
714
Copyright 2007 by the International Association for the Study of Lung Cancer